Abstract
Evidence of electronic patient-reported outcomes (ePROs) has been a significant innovation in PRO endpoint assessment in clinical trials. Yet, the health technology assessment (HTA) agencies’ perceptions of the use of ePRO measurement during clinical trials and implications for the benefit assessments are unknown. We aim to synthesize the advantages of using ePRO in clinical trials and to identify key HTA guidance that may inform future clinical trial design.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
